Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 12/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.34 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30834142 | 0.84 | PDE3A (0.36) | MAP4K4 | |
| SCHEMBL27201474 | 0.81 | HRH4 (0.51) | HRH4HRH3KDM4EMAP4K4 | |
| SCHEMBL27201357 | 0.72 | MAP4K4 (0.48) | HRH4HRH3MAP4K4GBA1 | |
| SCHEMBL27201287 | 0.71 | MAP4K4 (0.47) | HRH4HRH3MAP4K4 | |
| SCHEMBL3753632 | 0.70 | HRH4 (0.67) | HRH4HRH3 | |
| SCHEMBL27201604 | 0.69 | MAP4K4 (0.45) | HRH4HRH3KDM4EMAP4K4MEN1 | |
| SCHEMBL1616617 | 0.69 | HRH4 (1.00) | HRH4HRH3 | |
| SCHEMBL605954 | 0.68 | HRH4 (0.57) | HRH4HRH3KDM4E | |
| SCHEMBL27201320 | 0.68 | MAP4K4 (0.46) | HRH4HRH3MAP4K4 | |
| SCHEMBL602440 | 0.68 | HRH4 (0.67) | HRH4HRH3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-25 | — | — | US | claimed |
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | GID4, MDM2, XIAP | HRH4 4074/4885HRH3 4300/4885KDM4E 1293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.